ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays Consideration Of New New Heavy Particle Therapy Studies

March 8, 1985

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

July 27, 2012

Byrd Permits NCI to Reallocate WVU Money

June 21, 1985

COMMIT Moving Into Implementation

July 15, 1988

Centers Core Support To Be Trimmed By Dropping Funds for Scientists Salaries, Shared Resources

September 23, 1977

In Brief: Longmire Reappointed to Panel; New Organ System Group For Brain-CNS Tumors Asked

April 26, 1985